Erin L. Volk - Concepedia

Concepedia

Author

Erin L. Volk

New York State Department of Health

Also Known As

E L Volk, Erin L Volk, Erin L. Volk, Erin Volk

17

Publications

1.1K

Citations

10

H-Index

44

Concepts

All Affiliations

New York State Department of Health Wadsworth Center University at Albany, State University of New York St. Jude Children's Research Hospital National Taiwan University Hospital

EL

About

Erin L. Volk is an author at New York State Department of Health specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.1K
2	Cell Biology	8	8	974
3	Health Sciences	4	4	606
4	Natural Sciences	2	2	198
5	Cellular Physiology	1	1	184

Erin L. Volk

×

10

Publications

1.1K

Citations

10

H-Index

	Year	Citations
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Erin L. Volk, Kate M. Farley, Yan Wu, PubMed Breast OncologyMolecular BiologyCancer BiologyTumor BiologyDrug Resistance	2002	249
Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Erin L. Volk, Erasmus Schneider PubMed Breast OncologyMethotrexate Polyglutamate TransporterBcrp SubstrateCancer BiologyTumor Biology	2003	216
The Product of the ABC Half-Transporter Gene ABCG2 (BCRP/MXR/ABCP) Is Expressed in the Plasma Membrane Emmanuelle Rocchi, Alexey Khodjakov, Erin L. Volk, Biochemical and Biophysical Research Communications Molecular PhysiologySignal TransductionPlasma MembraneNatural SciencesMembrane Transport	2000	184
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Erin L. Volk, Kyle H. Rohde, M. Rhee, PubMed Methotrexate Cross-resistanceBreast OncologyMtx ResistantTumor BiologyDrug Resistance	2000	124
Antibody-Mediated Elimination of the Obligate Intracellular Bacterial Pathogen<i>Ehrlichia chaffeensis</i>during Active Infection Gary M. Winslow, Eric J. Yager, Konstantin Shilo, Infection and Immunity Pathogenic MicrobiologyMicrobial PathogensHumoral ResponseImmunologyBacterial Pathogens	2000	120
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells James Chih‐Hsin Yang, Erasmus Schneider, Min‐Liang Kuo, Biochemical Pharmacology Tumor BiologyBreast OncologyMedicineCancer Cell BiologyCancer Genomics	2000	112
Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Sri K. Diah, Pamela K. Smitherman, Julie Aldridge, PubMed Tumor BiologyMrp1 SubstratesBreast OncologyMitoxantrone TransportMedicine	2001	58
MDM2-A, a common <i>Mdm2</i> splice variant, causes perinatal lethality, reduced longevity and enhanced senescence Erin L. Volk, Katja Schuster, Katie Nemeth, Disease Models & Mechanisms	2008	20
The MDM2-A Splice Variant of MDM2 Alters Transformation <i>In vitro</i> and the Tumor Spectrum in Both Arf- and p53-Null Models of Tumorigenesis Erin L. Volk, Liying Fan, Katja Schuster, Molecular Cancer Research Mdm2-a Splice VariantCancer BiologyTumor BiologyP53 FunctionTumor Heterogeneity	2009	17
MDM2 displays differential activities dependent upon the activation status of NFκB Misty D. Cheney, Pamela McKenzie, Erin L. Volk, Cancer Biology & Therapy Molecular BiologyCell DeathTumor BiologyMdm2 ExpressionDifferential Activities	2008	14

Page 1